FOOD AND DRUG ADMINISTRATION ISSUES NOTICE: REVOCATION OF EMERGENCY USE OF A DRUG PRODUCT DURING THE COVID-19 PANDEMIC; AVAILABILITY

WASHINGTON, July 29 -- Food and Drug Administration has issued a notice called: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability.

The notice was published in the Federal Register on July 29 by Grace R. Graham, Deputy Commissioner for Policy, Legislation, and International Affairs.

Summary: The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorizations (EUAs) (the Authorizations) issued to Regeneron Pharmaceuticals, Inc. (Regeneron) for REGEN-COV (casirivimab and imdevimab administered together), to GlaxoSmithKline LLC (GSK) for sotrovimab, to Eli Lilly and Company (Lilly) for bebtelovimab, and to AstraZeneca Pharmaceuticals LP (AstraZeneca) for EVUSHELD (tixa...